Publication

Combined Sarcoidosis and Idiopathic Pulmonary Fibrosis (CSIPF): Coincidence, Association or Mimicry?

Journal Paper/Review - Feb 21, 2022

Units
Keywords
PubMed
Doi
Link
Contact

Citation
Kluckert J, Brutsche M. Combined Sarcoidosis and Idiopathic Pulmonary Fibrosis (CSIPF): Coincidence, Association or Mimicry?. Annals of Clinical Case Reports 2022; 7
Project
Type
Journal Paper/Review (English)
Journal
Annals of Clinical Case Reports 2022; 7
Publication Date
Feb 21, 2022
Issn Print
Issn Electronic
2474-1655
Pages
Publisher
Remedy Publications LLC. (Belmont, California)
Brief description/objective

Clinical Image
A 70-year old patient with longstanding history of sarcoidosis (initially ATS- stage II), presented
with progressive dyspnea and dry cough. Although corticosteroid therapy initially improved lung
function, a decline (Figure 1) was observed. Thoracic CT-scan was compatible with definite unusual
interstitial pneumonia potentially engrafted on the preexisting sarcoidosis. After multidisciplinary
discussion antifibrotic therapy with Nintedanib was started. Lung function and fibrosis on the
CT-scan improved (Figure 1, 2). Collins et al. [1] found a series of cases and coined the term
“Combined Sarcoidosis and Idiopathic Pulmonary Fibrosis CSIPF”. IPF is defined as fibrosis
without inflammation and sarcoidosis as a multisystem chronic inflammatory condition – these supposedly being two distinct entities [2,3]. Did we experience
coincidence, association or mimicry between these two entities?
Lucky enough antifibrotic treatments is also licensed for progressive
non-IPF fibrotic lung diseases.